Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry
One year after starting ETI, many pwCF who were initially positive for various CF-related pathogens, shifted to a negative status, a change less common before ETI. These findings suggest that ETI reduces airway infections, with benefits extending into the second year of treatment, although some pwCF continue to carry these pathogens despite treatment.
Authors
- Dario Prais (ORCID: https://orcid.org/0000-0002-4165-0144)
- Eitan Kerem (ORCID: https://orcid.org/0000-0002-4635-386X)
- Virginia De Rose (ORCID: https://orcid.org/0000-0001-5069-4416)
- Meir Mei‐Zahav (ORCID: https://orcid.org/0000-0002-6683-0264)
- Mordechai Pollak (ORCID: https://orcid.org/0000-0002-3793-200X)
- Annalisa Orenti (ORCID: https://orcid.org/0000-0002-0932-2757)
- Simone Gambazza (ORCID: https://orcid.org/0000-0002-6225-2989)
Institutions
- Tel Aviv University (IL)
- University of Milan (IT)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Schneider Children's Medical Center (IL)
- Ariel University (IL)
- University of Turin (IT)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1183/23120541.01248-2024
- Citations
- 9
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 13.67